Literature DB >> 1279748

Time courses of PIVKA-II and AFP levels after hepatic artery embolization and hepatic artery infusion against hepatocellular carcinoma: relation between the time course and tumor necrosis.

K Kishi1, T Sonomura, K Mitsuzane, N Nishida, M Kimura, M Satoh, R Yamada, N Kodama, M Kinoshita, H Tanaka.   

Abstract

We examined 35 untreated patients with unresectable hepatocellular carcinoma who exhibited positivity for both plasma PIVKA-II and serum AFP, and studied the weekly course of these markers from the pre-TAE or -HAI period to the third week of treatment. We correlated changes in these markers with the tumor necrosis rate and the time course on X-ray CT images. One week after TAE, the tumor necrosis rate and the time course of PIVKA-II showed a significant correlation (r = 0.7), while the correlation was between the time course of AFP and the tumor necrosis rate was insignificant (r = 0.2). At two and three weeks after TAE, both the time course of AFP and PIVKA-II showed significant correlations with the tumor necrosis rate. In 16 patients with tumor necrosis rates of not less than 90%, the mean of the actual half-life (AHL) of PIVKA-II was 3.2 days, the shortest was 1.83 days, and 75% of all AHLs clustered from two days to four days, while the mean and shortest AHLs of AFP were six days and 2.98 days, respectively, exhibiting a broader distribution. On the other hand, in three out of the nine cases of hepatocellular carcinoma complicated with portal tumor thrombi, PIVKA-II increased after HAI in spite of a reduction in tumor size. It was suggested that the PIVKA-II level requires careful interpretation in cases of portal vein obstruction after intensive hepatic arterial infusion of anticancer agents.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1279748

Source DB:  PubMed          Journal:  Radiat Med        ISSN: 0288-2043


  8 in total

1.  Tumor marker levels before and after curative treatment of hepatocellular carcinoma as predictors of patient survival.

Authors:  Atsushi Nanashima; Naota Taura; Takafumi Abo; Tatsuki Ichikawa; Ichiro Sakamoto; Takeshi Nagayasu; Kazuhiko Nakao
Journal:  Dig Dis Sci       Date:  2011-06-25       Impact factor: 3.199

2.  Rapid and early α-fetoprotein and des-γ-carboxy prothrombin responses to initial arterial infusion chemotherapy predict treatment outcomes of advanced hepatocellular carcinoma.

Authors:  Kenji Oyama; Masahiko Koda; Takaaki Sugihara; Manabu Kishina; Kenichi Miyoshi; Toshiaki Okamoto; Masanori Hodotsuka; Yuki Fujise; Tomomitsu Matono; Shiho Tokunaga; Kinya Okamoto; Keiko Hosho; Junichi Okano; Yoshikazu Murawaki
Journal:  Mol Clin Oncol       Date:  2015-03-03

3.  The Early Decline of α-Fetoprotein and Des-γ-Carboxy Prothrombin Predicts the Response of Hepatic Arterial Infusion Chemotherapy in Hepatocellular Carcinoma Patients.

Authors:  Shumpei Yamamoto; Hideki Onishi; Akinobu Takaki; Atsushi Oyama; Takuya Adachi; Nozomu Wada; Masahiro Sakata; Tetsuya Yasunaka; Hidenori Shiraha; Hiroyuki Okada
Journal:  Gastrointest Tumors       Date:  2020-04-21

4.  Transcatheter arterial chemoembolization (TACE) in the treatment of unresectable liver cancer.

Authors:  R Yamada; K Kishi; M Sato; T Sonomura; N Nishida; K Tanaka; Y Shioyama; M Terada; M Kimura
Journal:  World J Surg       Date:  1995 Nov-Dec       Impact factor: 3.352

5.  Identification of the Response-Related Biomarker of Bimonthly Hepatic Arterial Infusion Chemotherapy.

Authors:  Kei Moriya; Tadashi Namisaki; Hiroaki Takaya; Kosuke Kaji; Hideto Kawaratani; Naotaka Shimozato; Yasuhiko Sawada; Akitoshi Douhara; Shinya Sato; Masanori Furukawa; Koh Kitagawa; Takemi Akahane; Hitoshi Yoshiji
Journal:  J Clin Med       Date:  2021-02-07       Impact factor: 4.241

6.  A new therapeutic assessment score for advanced hepatocellular carcinoma patients receiving hepatic arterial infusion chemotherapy.

Authors:  Issei Saeki; Takahiro Yamasaki; Norikazu Tanabe; Takuya Iwamoto; Toshihiko Matsumoto; Yohei Urata; Isao Hidaka; Tsuyoshi Ishikawa; Taro Takami; Naoki Yamamoto; Koichi Uchida; Shuji Terai; Isao Sakaida
Journal:  PLoS One       Date:  2015-05-20       Impact factor: 3.240

7.  Clinical significance of AFP and PIVKA-II responses for monitoring treatment outcomes and predicting prognosis in patients with hepatocellular carcinoma.

Authors:  Hana Park; Jun Yong Park
Journal:  Biomed Res Int       Date:  2013-12-29       Impact factor: 3.411

8.  Dietary and genetic influences on hemostasis in a Yup'ik Alaska Native population.

Authors:  Nicholas T Au; Morayma Reyes; Bert B Boyer; Scarlett E Hopkins; Jynene Black; Diane O'Brien; Alison E Fohner; Joe Yracheta; Timothy Thornton; Melissa A Austin; Wylie Burke; Kenneth E Thummel; Allan E Rettie
Journal:  PLoS One       Date:  2017-04-04       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.